A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Summary

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the treatment effect, safety, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

Timeline

Start

2024-03-05

Primary completion

2025-04-22

Completion

2025-04-22

Drugs

Indications